Robotic-assisted placement of hepatic artery infusion pump for the treatment of colorectal liver metastases: Role of indocyanine green (with video)

2021 ◽  
Author(s):  
Mario Spaggiari ◽  
Kiara A Tulla ◽  
Gabriela Aguiluz ◽  
Pierpaolo Di Cocco ◽  
Lola Castro Gil ◽  
...  
Keyword(s):  
Indocyanine Green ◽  
Liver Metastases ◽  
Hepatic Artery ◽  
Colorectal Liver Metastases ◽  
Infusion Pump ◽  
Hepatic Artery Infusion ◽  
Robotic Assisted

Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases

2021 ◽  
Author(s):  
Michael P. O'Leary ◽  
Chongkai Wang ◽  
Jaideep Sandhu ◽  
Gautam K. Malhotra ◽  
Lucas W. Thornblade ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Hepatic Artery ◽  
Colorectal Liver Metastases ◽  
Infusion Pump ◽  
Hepatic Artery Infusion ◽  
Regional Therapy

scholarly journals Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis

2019 ◽  
Vol 37 (2) ◽  
pp. 333-339
Author(s):  
Changli Peng ◽  
Chunhui Zhou ◽  
Gang Li ◽  
Haiping Li ◽  
Liangrong Shi
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Liver Metastases ◽  
Hepatic Artery ◽  
Infusion Pump ◽  
Objective Response ◽  
Complete Response ◽  
Hepatic Artery Infusion ◽  
Significant Difference ◽  
Extrahepatic Metastases ◽  
Grade 3

AbstractTo evaluate the benefits and risks of hepatic artery infusion (HAI) gemcitabine and floxuridine (FUDR) in patients with nasopharyngeal carcinoma liver metastases. HAI catheter systems were implanted under the guide of digital subtract angiography (DSA) in 16 patients with unresectable nasopharyngeal carcinoma liver metastases. HAI gemcitabine and FUDR in combination with radiotherapy and systemic chemotherapy were delivered. Disease control rate (DCR) of intrahepatic lesions is 100%, objective response rate (ORR) of intrahepatic lesions is 87.5%, including 4 patients (25%) with complete response (CR), 10 patients (62.5%) with partial response (PR) and 2 patients (12.5%) with stable disease (SD). The median overall survival (mOS) was 30 months. There was no significant difference between patients with < 9 intrahepatic lesions and patients with ≥ 9 intrahepatic lesions (31 months vs. 24 months, P = 0.562). Patients without extrahepatic metastases has longer survival than patients with extrahepatic metastases (31 months vs. 17 months, P = 0.005). In all 72 cycles of HAI, the main grade 3/4 toxicities related to HAI include: leukopenia occur in 8 cycles (11.1%), thrombocytopenia in 5 cycles (6.9%), AST/ALT elevation in 12 cycles (16.7). Catheter related complications occurred in 2 patients (12.5%). HAI gemcitabine and FUDR is effective to improve DCR of intrahepatic lesions and prolong mOS for patients with nasopharyngeal carcinoma liver metastases, and is associated with a relative low rate of toxicity.

Sign in / Sign up

Export Citation Format

Share Document